The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.
Peter Martin
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Sin-Ho Jung
No relevant relationships to disclose
Jeffrey L. Johnson
No relevant relationships to disclose
Brandy Pitcher
No relevant relationships to disclose
Rebecca L. Elstrom
Employment or Leadership Position - Roche/Genentech
Nancy Bartlett
Research Funding - Celgene
Kristie A. Blum
No relevant relationships to disclose
Kristy L. Richards
Consultant or Advisory Role - Genentech
John Leonard
Consultant or Advisory Role - Celgene
Bruce D. Cheson
Consultant or Advisory Role - Celgene; Genentech